PATENT CLAIM ANALYSIS

Application Number: 16517111
Application Type: Utility
Filing Date: 2019-07
Publication Date: 2019-11
Patent Classification: ["514", "469000"]

Abstract:
One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least 1/2 hour prior to administration, no food at least 1 hour prior to administration, no food at least 1-1/2 hours prior to administration, no food at least 2 hours prior to administration, no food at least 2-1/2 hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.

Claim (Index 15):
The improvement of  claim 12 , wherein the patient has had no food for at least two hours prior to the administering.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 100.0
- Lexical Diversity: 2.375
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14511669', '16180316', '10802280', '14374257', '15382526']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6656713452337871
- 35 USC 102 Novelty (BERT): 0.5548492209900188
- Combined Prediction Score: 0.6545891328094103
- Mean Citation Score: 259.380482
- Max Citation Score: 409.59012
- Similarity Product: 272.56974352044585

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test